ArticleEJNMMI research2022
Assessing the accuracy of [
Article in EJNMMI research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Can pelvic lymph node dissection be spared in intermediate-risk prostate cancer patients with negative PSMA PET scan? A systematic review and diagnostic meta-analysis.Prostate cancer and prostatic diseases · 2026Pooled it
- Efficacy of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Pooled it
- Hitting the bullseye: PSMA-targeted small molecule drug conjugate for prostate cancer treatment.RSC advances · 2026Article
- Combining prostate-specific membrane antigen PET/CT with Memorial Sloan Kettering Cancer Center and Briganti 2012 nomograms enhances lymph node metastasis prediction in prostate cancer patients with a risk above 5.Asian journal of urology · 2026Article
- Focusing on Prostate-Specific Membrane Antigen in Precision Diagnosis and Treatment of Prostate Cancer.Biomedicines · 2026Review
- Diagnostic performance of conventional MRI using T1W and T2W for primary lymph node staging in intermediate- and high-risk prostate cancer patients prior to pelvic lymph node dissection.Abdominal radiology (New York) · 2026Observational
- The Role of Untraceable Sentinel Lymph Nodes in Prostate Cancer Patients Undergoing Radical Prostatectomy and Pelvic Lymph Node Dissection: Insights from an Ongoing Prospective Study.Journal of clinical medicine · 2025Article
- Lymph node disease in 2-deoxy-2-fluorodeoxyglucose positron emission tomography/computed tomography imaging: Advances in artificial intelligence-driven automatic segmentation and precise diagnosis.World journal of clinical oncology · 2025Review
- A fully automated AI-based method for tumour detection and quantification on [EJNMMI physics · 2025Article
- PSMA PET/CT for prostate cancer diagnosis: current applications and future directions.Journal of cancer research and clinical oncology · 2025Review
- The Role of 18F PSMA-1007 PET/CT in the Staging and Detection of Recurrence of Prostate Cancer, A Scoping Review.Cancers · 2025Review
- Exploring the Correlation Between Multiparameters Detected in Primary Prostate Cancer using F‑18 PSMA‑1007 PET/MRI and their Potential for Predicting Metastasis.Nuclear medicine and molecular imaging · 2025Article
- Diagnostic Accuracy of Molecular Imaging Techniques for Detecting Prostate Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2024Review
- To see clear is not enough; it is the action that counts.Translational andrology and urology · 2024Article
- PET/CT imaging 2 h after injection of [European journal of hybrid imaging · 2023Article
- Establishing 18F-PSMA-1007 Production in Armenia: Radiosynthesis and Comprehensive Quality Control.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
background[
objectiveOur aim was to assess the diagnostic accuracy of [ DESIGN, SETTING AND
participantsThe study was a retrospective cohort in a tertiary referral center. Men with prostate cancer that underwent surgical treatment for intermediate- or high-risk prostate cancer between May 2019 and August 2021 were included.
interventions[ OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: Sensitivity and specificity were calculated both for the entire cohort and for patients with lymph node metastasis ≥ 3 mm. Positive (PPV) and negative (NPV) predictive values were calculated. RESULTS AND LIMITATIONS: Among 104 patients included in the analyses, 26 patients had lymph node metastasis based on pathology reporting and metastases were ≥ 3 mm in size in 13 of the cases (50%). In the entire cohort, the sensitivity and specificity of [
conclusionsIn primary staging of intermediate- and high-risk prostate cancer, [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.